Ontology highlight
ABSTRACT:
SUBMITTER: Leonowens C
PROVIDER: S-EPMC4243903 | biostudies-literature | 2014 Sep
REPOSITORIES: biostudies-literature
Leonowens Cathrine C Pendry Carolyn C Bauman John J Young Graeme C GC Ho May M Henriquez Frank F Fang Lei L Morrison Royce A RA Orford Keith K Ouellet Daniele D
British journal of clinical pharmacology 20140901 3
<h4>Aims</h4>The aim of this phase 1, single centre, open label study in four patients with solid tumours was to determine the absolute bioavailability of a 2 mg oral dose of trametinib. Trametinib is an orally bioavailable, reversible and selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.<h4>Methods</h4>A microtracer study approach, in which a 5 μg radiolabelled i.v. microdose of trametinib was given concomitantly with an unlabelled 2 mg oral tablet formulation, was ...[more]